A recent study found that bexicaserin, a drug that activates certain serotonin receptors, was safe and helped lower motor seizure frequency in people with different types of DEE.

What It’s About

Researchers tested an antiseizure medicine in people with Dravet syndrome, Lennox-Gastaut syndrome, and a mixed group labeled “DEE Other”. They found that bexicaserin was well tolerated and reduced countable motor seizures more effectively than a placebo in all three groups. Because of these results, the drug will now move into Phase III trials, where it will be tested in even more people.

Why It Matters

While seizure reduction may be only one priority for the KCNQ2 community, this study’s successful use of a broad “DEE Other” category is important. It shows that combining people with different DEEs in the same trial can still lead to meaningful results. This could help future clinical trials include more DEE conditions, increasing opportunities for rare groups to access potential treatments.  

The Quick Term

Placebo: A pill or treatment that has no active drug in it. Placebos help researchers make fair comparisons so they can be sure any improvements they see are caused by the medicine and not by chance or expectations. 

Link

Read Article